Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy

Gut

Volumn 64, Issue 11, 2015, Pages 1715-1720

  Zhang, Wei ^a,b   Chen, Qi ^a,b   Liang, Xiao ^a,b   Liu, Wenzhong ^a,b   Xiao, Shudong ^a,b   Graham, David Y ^c   Lu, Hong ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BEIJING HOSPITAL   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CARBON 13; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; ANTIINFECTIVE AGENT; BISMUTH; PROTON PUMP INHIBITOR;

ADULT; AGAR DILUTION; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIGASTRIC PAIN; ERADICATION THERAPY; FATIGUE; FEMALE; FEVER; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN ALLERGY; TASTE DISORDER; TREATMENT DURATION; UREA BREATH TEST; ADOLESCENT; DRUG COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BISMUTH; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LANSOPRAZOLE; MALE; METRONIDAZOLE; MIDDLE AGED; PROTON PUMP INHIBITORS; YOUNG ADULT;

EID: 84947599674     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-309900     Document Type: Article

References (28)

1. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
2. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
3. Sun QJ, Liang X, Zheng Q, et al. Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai. World J Gastroenterol 2010;16:5118-21.
4. Megraud F. Helicobacter pylori and antibiotic resistance. Gut 2007;56:1502.
5. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84.
6. Liu WZ, Xie Y, Cheng H, et al. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. J Dig Dis 2013;14:211-21.
7. Graham DY, Osato MS, Hoffman J, et al. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol Ther 2000;14:745-50.
8. Megraud F. The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. Therap Adv Gastroenterol 2012;5:103-9.
9. Van der Wouden EJ, Thijs JC, Zwet AA, et al. The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. Aliment Pharmacol Ther 1999;13:297-302.
10. Bardhan K, Bayerdorffer E, Veldhuyzen et al The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. Helicobacter 2000;5:196-201.
11. Asaka M, Kato M, Takahashi S, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010;15:1-20.
12. Garcia N, Calvet X, Gene E, et al. Limited usefulness of a seven-day twice-a-day quadruple therapy. Eur J Gastroenterol Hepatol 2000;12:1315-18.
13. Dore MP, Farina V, Cuccu M, et al. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter 2011;16:295-300.
14. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007;26:343-57.
15. Sun Q, Liang X, Zheng Q, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010;15:233-8.
16. Nishizawa T, Maekawa T, Watanabe N, et al. Clarithromycin versus metronidazole as first-line Helicobacter pylori eradication: a multicenter, prospective, randomized controlled study in Japan. J Clin Gastroenterol 2015;49:468-71.
17. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014;12:177-86.e3; discussion e12-3.
18. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004;20:1071-82.
19. Abadi AT, Taghvaei T, Mobarez AM, et al. Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. J Microbiol 2011;49:987-93.
20. Songur Y, Senol A, Balkarli A, et al. Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment. Am J Med Sci 2009;338:50-3.
21. Saad RJ, Schoenfeld P, Kim HM, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006;101:488-96.
22. Yang JC, Lin CJ, Wang HL, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2015;13:895-905.e5.
23. Sanchez-Delgado J, Garcia-Iglesias P, Castro-Fernandez M, et al. High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2012;36:190-6.
24. Liao J, Zheng Q, Liang X, et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013;18:373-7.
25. Zhou L, Zhang J, Chen M, et al. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. Am J Gastroenterol 2014;109:535-41.
26. de Boer WA. How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint. J Clin Gastroenterol 1996;22:313-16.
27. Al-Eidan FA, McElnay JC, Scott MG, et al. Management of Helicobacter pylori eradication - the influence of structured counselling and follow-up. Br J Clin Pharmacol 2002;53:163-71.
28. Wheeldon TU, Granstrom M, Hoang TT, et al. The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication. Aliment Pharmacol Ther 2004;19:1315-21.